EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties

Authors :: Robert Hodgson
Abdullah Pandor
Rob Riemsma
Jonathan Shepherd
Xavier Armoiry
Eva Kaltenthaler
Bram Ramaekers
Nerys Woolacott
Nasuh Büyükkaramikli
Mark Stevenson
Miriam Brazzelli
Eleanor Kotas
Sabine Grimm
Angela Boland
Rui V. Duarte
Manuela A. Joore
Martin Hoyle
Rumona Dickson
Steve Edwards
Health Economics (HE)
Health Technology Assessment (HTA)
RS: CAPHRI - R2 - Creating Value-Based Health Care
MUMC+: KIO Kemta (9)
Health Services Research
Source :: Applied Health Economics and Health Policy, 16(4), 429-432. Springer International Publishing AG, Applied Health Economics and Health Policy, Applied Health Economics and Health Policy, 16(4), 429-432. Adis International Ltd, APPLIED HEALTH ECONOMICS AND HEALTH POLICY
Publication Year :: 2018
Publisher :: Springer Science and Business Media LLC, 2018.
Abstract: The Evidence Review Group members that contributed to this editorial are funded by the UK NIHR HTA Programme. The views and opinions expressed are those of the authors and do not necessarily reflect those of the UK Department of Health and the NIHR.

Full Text Access

Tools